Aclaris Therapeutics, Inc. ACRS 深 沪
等待开盘 08-11 09:30:00 美东时间
5.90
-0.010
-0.17%
华盛通- 最 高5.99
- 今 开5.92
- 成交量 159.37万股
- 最 低 5.67
- 昨 收 5.91
- 总市值 82.40万
- 52周最高 6.515
- 市盈率 静 --
- 换手率 1.14%
- 52周最低 1.74
- 委 比 -2.91%
- 总股本 0.00亿
- 历史最高 33.88
- 量 比 0.52
- 振 幅 5.41%
- 历史最低 0.5902
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocity against fu...
08-10 20:49
Aclaris Updates At-The-Market Equity Sales Agreement
Aclaris Therapeutics ( ($ACRS) ) has provided an update. On August 6, 2026, Acl...
08-07 06:22
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics reported Q2 2026 financial results with a net loss of $21.5 million, up from $15.4 million in Q2 2025, driven by increased R&D expenses for ATI-052 and ATI-9494. The company highlighted positive Phase 1a results for its bispecific antibody ATI-052, supporting extended dosing potential, and reaffirmed timelines for upcoming Phase 1b POC trials in asthma and atopic dermatitis. Aclaris also confirmed plans to initiate a Phase 2b...
08-06 10:59
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. Shares of SL Science Holding Ltd (NASDAQ:SLBT) fell sharply in pre-market trading after the company reported its financial results for the full year ended Dec. 31. Net revenue fell by or 35% to around...
06-22 20:02
美股夜盘 | Sagtec Global Ltd. Class A涨92.93%，LEIFRAS Co涨37.26%
Akanda Corp涨-17.75%；BTQ Technologies涨-11.72%；Aclaris Therapeutics, Inc.涨-11.11%
06-22 08:05
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday
Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.
06-03 21:13
Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year.
05-07 21:23
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
05-05 20:45
